Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
101
resultados
Última actualización
18/03/2026 [07:23:00]
Resultados 25 a 50 de 101
Resumen de: US20260041735A1
The present disclosure relates to a recombinant expression vector for secretion of interleukin-21 and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising an flgM gene and an interleukin-21 gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.
Resumen de: EP4692335A1
An aim of the present disclosure is: (i) to provide a novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, or a bacteriolytic agent consisting of the same; (ii) to provide a bacteriophage having a wide host range for bacteria of the genus Salmonella, or a bacteriolytic agent consisting of the same; (iii) to provide a host-specific bacteriophage or an effective Salmonella bacteriolytic agent consisting of the same; or (iv) provide a bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, or a bacteriolytic agent consisting of the same. The present disclosure provides: a bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same.
Resumen de: EP4692334A1
An aim of the present invention is to provide a bacteriophage having a wide host range for bacteria of the genus Salmonella. The present invention is a bacteriophage with bacteriolytic activity against bacteria of the genus Salmonella, in which the bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence.
Resumen de: WO2026027798A1
A yeast biomass composition is formed by culturing a strain of yeast in a substrate such as whey permeate to product a yeast broth, dewatering the broth to produce yeast biomass, and hydrolysing the yeast biomass. The yeast biomass composition finds utility as a feed additive for broiler chickens to reduce the adherence of pathogenic bacteria like Salmonella and E.coli to the gut wall of the chickens, thereby reducing intestinal stress and improving life daily weight gain in the chickens.
Resumen de: US20260035440A1
The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.
Resumen de: WO2026030756A2
The composition and methods of treatment disclosed or contemplated herein include compositions and methods of treatment for liver-related diseases. The overall treatment strategy would involve the identification of a target protein or receptor within the liver that is responsible for ongoing liver injury. The strain of orally administered Salmonella Typhimurium that colonizes the liver would be engineered to secrete a particular protein or nanobody that would stop and/or reverse the progressive hepatic disease
Resumen de: KR20260015111A
본 개시는 편두통 진단을 위한 정보 제공 방법에 관한 것으로서, 보다 상세하게는 생물학적 시료에서 제멜라 헤몰리산스, 센티페다 페리오돈티, 카르디오박테리움 발바룸, 카토넬라 모르비 및 셀레노모나스 녹시아로 이루어진 군에서 선택된 적어도 하나의 박테리아의 상대적 풍부도를 측정하는 단계를 포함함으로써 환자의 통증 또는 거부감 없이 정확하고 신속한 편두통 진단을 가능하게 하는 방법에 관한 것이다.
Resumen de: WO2025003119A1
The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
Resumen de: CN121427773A
The invention discloses lactobacillus johnsonii for preventing and treating pullorum disease salmonellosis and application of the lactobacillus johnsonii, and belongs to the field of microorganisms. According to the invention, a strain of Lactobacillus johnsonii LMZ8 is separated and screened, and the preservation number of the strain of Lactobacillus johnsonii LMZ8 is GDMCC No: 66614. The lactobacillus johnsonii LMZ8 is good in acid resistance and has certain tolerance to high-concentration cholate. Experimental results show that the lactobacillus johnsonii LMZ8 can effectively inhibit the growth of various pathogenic bacteria such as salmonella typhimurium and salmonella enteritidis, especially has a prominent inhibition effect on five strains of multi-drug-resistant salmonella pullorum with no same drug resistance spectrum, can effectively prevent and treat the pullorum disease caused by salmonella pullorum, and improves the growth performance of chicks. The lactobacillus johnsonii LMZ8 shows remarkable development potential in the aspects of preventing and controlling food-borne pathogenic bacteria and preventing and treating diseases such as pullorum disease, and has a wide development prospect.
Resumen de: WO2026024938A1
Methods of reducing or preventing intrauterine transmission of Salmonella Dublin in a subject, typically a cow, are provided. The methods include a first administration, and optionally second or more administrations, to a pregnant cow of an effective amount of an immunogenic composition to induce an immune response against S. Dublin in the cow. In some forms, the cow is infected with S. Dublin. In some forms, two or more cows are treated in parallel, for example, all cows that inseminated or otherwise became pregnant in parallel. Typically, the first administration, and optionally second or more administrations, are administered to the cow at a time(s) that reduces intrauterine transmission of S. Dublin infection from the cow to one or more of her calves compared to unvaccinated control cows and/or cows administered according to a different administration regimen. Exemplary methods of administration are provided.
Resumen de: US20260027165A1
The present disclosure relates to a recombinant expression vector for secretion of chlorotoxin and an attenuated Salmonella strain transformed therewith, and provides: a recombinant expression vector comprising a flgM gene and a chlorotoxin gene; an attenuated Salmonella strain transformed therewith; and a pharmaceutical composition for cancer treatment, comprising the attenuated Salmonella strain.
Resumen de: US20260028377A1
The present invention relates to a gene construct characterized by encoding a fusion protein of flgM and Strep-tag through the linkage of an anti-sigma factor flgM gene and a gene encoding Strep-tag, enabling the expression of Strep-tag on the surface of an anti-cancer strain that can target tumor sites and stimulate immune activity, and to an anti-cancer adjuvant and tumor imaging agent that, when transformed by this construct, exhibits anti-cancer activity itself and can be effectively utilized in the diagnosis and treatment of tumor cells together with anti-cancer substances or contrast agents labeled with substances specifically interacting with Strep-tag.
Resumen de: WO2024197078A2
Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.
Resumen de: GB2700365A
Method of performing SBA assay comprising: preparing media and buffer; preparing bacterial stock with a mother culture stock, media and buffer; diluting bacterial stock with buffer to obtain a diluted bacterial stock; adding test serum, complement, diluted bacterial stock, and buffer to form an assay solution; incubating assay solution, spotting it on an agar plate and incubating the plate; calculating antibody titre to determine the serum bactericidal activity. Kit or system for performing said SBA assay wherein they contain said media, buffer, bacterial stock and complement and optionally a package insert or label providing instructions to perform the SBA assay. Method for performing a serum bactericidal assay comprising preparing a bacterial stock with a mother culture stock and media, diluting the bacterial stock 1:100-1:6000 with buffer to obtain diluted bacterial stock, adding test serum, complement, diluted bacterial stock, and buffer to form an assay solution; incubating the assay solution, spotting it on an agar plate and incubating the plate; calculating antibody titre to determine the serum bactericidal activity. Figure 1
Resumen de: CN121380294A
The invention discloses a salmonella typhimurium fluorescence detection method based on dual signal amplification, and relates to the technical field of microbiological detection.The method comprises the specific steps that firstly, SNA1 and SNA2 probes are constructed, related chains are co-modified on the surfaces of gold nanoparticles through a freezing method, and part of sequences are closed; then preparing an Apt.-F compound; then incubating the sample and the compound; then starting a dual signal amplification reaction; and finally, detecting the fluorescence intensity by using a fluorospectro photometer, and quantifying the salmonella typhimurium according to the relationship between the fluorescence intensity and the bacterium concentration. According to the invention, two kinds of functionalized SNA probes are constructed, the aptamer and DNAzyme are arranged, a dual signal amplification pathway is established, target bacteria are accurately identified through the aptamer, a trigger chain is released to start chain replacement, a fluorophore is released, the detection sensitivity is improved, the probe design is optimized to ensure specificity, the process is simplified, and rapid quantification is realized; an efficient scheme is provided for trace pathogenic bacterium detection.
Resumen de: CN121380278A
The invention discloses a salmonella sodium hypochlorite tolerance evaluation method, which comprises: (1) preparing a bacterial liquid, and (2) carrying out a cell viability chromogenic reaction: adding 100 mu L of a bacterial suspension and 100 mu L of a sodium hypochlorite solution with a gradient concentration into each well of a 96-well plate, standing for 30 min under a room temperature condition, adding 20 mu L of a 2.5 wt% sodium thiosulfate solution, standing for 10 min under a room temperature condition, and carrying out a cell viability chromogenic reaction, adding 20 mu L of a 10 * resazurin indicator, and culturing at a constant temperature of 37 DEG C for 4 h; and (3) salmonella tolerance grade determination based on the MIC value: taking the lowest sodium hypochlorite concentration of blue pores in a 96-pore plate as the MIC value, and the higher the MIC value is, the stronger the tolerance is. According to the method, the tolerance of the salmonella to the sodium hypochlorite can be intuitively and quickly judged through the chromogenic reaction.
Resumen de: CN121379980A
The invention discloses a salmonella bacteriophage SaPA-9 with a wide host spectrum and application of the salmonella bacteriophage SaPA-9. The preservation number of the salmonella bacteriophage SaPA-9 with the wide host spectrum is GDMCC No: 63416-B1. The bacteriophage SaPA-9 has an ultra-wide host spectrum, not only has a relatively strong killing effect on salmonella, but also plays a role in escherichia coli, has genome safety and in-vivo and in-vitro safety, is suitable for large-scale salmonella or escherichia coli infection resistance, and has a better application effect.
Resumen de: CN121379903A
The invention relates to the technical field of microorganisms, and particularly discloses a lactobacillus paracasei KQNIU, a microbial preparation and application of the lactobacillus paracasei KQNIU. The Lactobacillus paracasei KQNIU is preserved in the China General Microbiological Culture Collection Center on August 25, 2025, the preservation number is CGMCC No.35739, and the Lactobacillus paracasei KQNIU is classified and named as Lactobacillus paracasei, and the Lactobacillus paracasei KQNIU is named as Lactobacillus paracasei KQNIU. The Lactobacillus paracasei KQNIU is named as Lactobacillus paracasei KQNIU. The lactobacillus paracasei KQNIU provided by the invention has good gastrointestinal tract tolerance, has an inhibition effect on pathogenic bacteria such as escherichia coli, salmonella and the like, can be prepared into a microbial preparation or a feed additive for preventing and treating calf diarrhea, replaces antibiotics and realizes green and healthy breeding.
Resumen de: WO2025003117A1
The present invention relates to a gelled reaction medium for detecting, identifying, and/or isolating at least one Shiga toxin-producing strain of E. coli, the reaction medium comprising: - at least one toxin inducer, - at least one agglutinating conjugate comprising at least one specific binding partner of STX1 and/or at least one specific binding partner of STX2, coupled to a nanoparticle; - a concentration gradient of a compound for inhibiting non-target bacteria. The present invention also relates to the associated method for detecting and/or isolating Shiga toxin-producing E. coli which is likely to be present in a sample comprising enterobacteria.
Resumen de: CN121378418A
The invention discloses a group of antibacterial polypeptides aiming at gram-negative bacteria, and belongs to the technical field of biological medicines. According to the invention, a group of antibacterial peptides is obtained through screening, and the antibacterial peptides have good broad-spectrum antibacterial performance on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia. Wherein the hemolytic activity and toxicity of the antibacterial peptides 11A-1, 11A-4 and 11A-5 are lower than therapeutic concentration threshold values, and the antibacterial peptides 11A-1, 11A-4 and 11A-5 can be used for preparing drugs or medical products for treating multi-drug-resistant bacterial infection.
Resumen de: CN121369432A
The invention belongs to the technical field of bacteriostatic agents and application thereof, and particularly relates to a Tibetan medicine composition, a preparation method and application of the Tibetan medicine composition in bacteriostatic products. The traditional Tibetan medicine sophora moorcroftiana seeds, cortex phellodendri, myricaria laxiflora and artemisia sieversiana are compounded, active ingredients in the traditional Tibetan medicine sophora moorcroftiana seeds, cortex phellodendri, myricaria laxiflora and artemisia sieversiana are extracted, the water-soluble plant source bacteriostatic agent with a good bacteriostatic effect is prepared, and the alkaloid content in the obtained bacteriostatic agent is 2.06-2.78 mg/g by optimizing an extraction process; in addition, the Tibetan medicine composition provided by the invention has a good inhibition effect on ten microbial bacteria such as escherichia coli, candida albicans, staphylococcus aureus, bacillus subtilis, propionibacterium acnes, streptococcus mutans, salmonella enteritidis, pseudomonas aeruginosa, porphyromonas gingivalis and staphylococcus epidermidis, and has universal antibacterial activity; the method can be widely applied to antibacterial products in various fields.
Resumen de: CN121380063A
The invention discloses CRISPR (clustered regularly interspaced short palindromic repeats)-based food-borne pathogenic bacterium crRNA (crRNA), a kit, a multiple detection method and application, and belongs to the technical field of food safety detection. Specific genes of salmonella typhimurium (invA), staphylococcus aureus (femB), listeria monocytogenes (hly) and vibrio parahaemolyticus (toxR) are used as target genes for detection, an RPA primer and crRNA are designed for each gene, a quadruple RPA-CRISPR reaction system is established, the dual technical advantages of RPA amplification and a CRISPR system are combined, the detection sensitivity of the method is smaller than 10 copies/L, the detection time is greatly shortened, and the detection efficiency is greatly improved. And visual detection is realized through a blue light detector.
Resumen de: KR20260011330A
본 발명은 프로테오즈 펩톤, D-소르비톨, 페놀 레드, 뉴트럴 레드, 크리스탈 바이올렛 및 사카로스를 포함하는 살모넬라 균의 선별 또는 선택 배지 조성물에 관한 것이다.
Resumen de: CN120917035A
The present invention relates to protein bacteriocins (PBs) as therapeutic agents, and in particular to protein complexes comprising two or more PB molecules associated with a protein scaffold comprising a homologous immune protein domain against an effector portion of the corresponding PB. In particular, the present invention provides an antibacterial protein complex comprising: (a) a first PB molecule and a second PB molecule; and (b) an immune protein scaffold comprising a first immune protein domain and a second immune protein domain; wherein the first immune protein domain and the second immune protein domain are non-covalently bound to the first PB molecule and the second PB molecule, respectively.
Nº publicación: US20260022888A1 22/01/2026
Solicitante:
BRIGGS PAULETTE NICOLE [US]
Briggs Paulette Nicole
Resumen de: US20260022888A1
The purpose of the (Fort's Gloves, Dry and Hold Pail) is to prevent moisture that causes the spread of bacteria from restrooms that is the cause of influenza, streptococcus, E coli, Hepatitis, MRSA, Salmonella, Shigella, and Norovirus. The pail is a new creation except for the authentic manuscript and cursive text. There is a distinct difference from the usual and traditional utility pails each community uses, because of the holder for the moisture elimination products that prevents contaminated water from spilling to the floor. Fecal and Trash water could potentially cause mildew growth on the gloves and the pail. The Dry & Hold container overall is a new Invention and a cleaner choice for the environment because the design prevents disease, foul odors.
BOPI
Sede Electrónica
